Intensity Therapeutics Files 8-K

TL;DR

Intensity Therapeutics filed an 8-K on 12/4/25, but it's light on details.

AI Summary

Intensity Therapeutics, Inc. filed an 8-K on December 4, 2025, reporting on 'Other Events' and 'Financial Statements and Exhibits'. The filing does not contain specific financial figures or event details beyond the reporting of these categories.

Why It Matters

This 8-K filing indicates that Intensity Therapeutics, Inc. has submitted a report to the SEC, but it lacks specific details about the events or financial statements being disclosed.

Risk Assessment

Risk Level: low — The filing is a standard procedural report without specific material events or financial disclosures that would indicate immediate risk.

Key Players & Entities

• INTENSITY THERAPEUTICS, INC. (company) — Registrant
• December 4, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 1 Enterprise Drive, Suite 430 Shelton, CT 06484 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nge on Which Registered: Common Stock, $0.0001 par value per share INTS The Nasdaq Sto
• $30 million — market" offering program (the "ATM") to $30 million. While this filing increases the availa

Filing Documents

• intensity-20251204.htm (8-K) — 27KB
• exhibit51-8xkatm.htm (EX-5.1) — 12KB
• image_1.jpg (GRAPHIC) — 12KB
• image_3.jpg (GRAPHIC) — 33KB
• 0001567264-25-000109.txt ( ) — 225KB
• intensity-20251204.xsd (EX-101.SCH) — 2KB
• intensity-20251204_lab.xml (EX-101.LAB) — 23KB
• intensity-20251204_pre.xml (EX-101.PRE) — 13KB
• intensity-20251204_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events On December 4, 2025, Intensity Therapeutics, Inc. (the "Company") filed a prospectus supplement to increase the capacity of its existing "at-the-market" offering program (the "ATM") to $30 million. While this filing increases the available capacity under the ATM, the Company is under no obligation to issue any shares (the "Shares") pursuant to the program. The expanded facility is intended to enhance the Company's financial flexibility, providing an efficient mechanism to access capital if, and when, deemed appropriate. Any utilisation of the ATM will be at the discretion of the Company, taking into account prevailing market conditions and strategic priorities. As previously disclosed, the ATM is conducted pursuant to the at the market offering agreement (the "Offering Agreement"), dated July 3, 2024 (the "Offering Agreement") by and among the Company and H.C. Wainwright & Co. LLC (the "Sales Agent). Accordingly, pursuant to the prospectus supplement, the amount of shares of the Company's common stock, par value $0.0001 per share, that the Company may issue under the Offering Agreement has been increased to an aggregate of $30 million of Shares. There can be no assurance that the Sales Agent will be able to complete future placements pursuant to the Offering Agreement, even if instructed to do so. The number of Shares that the Company may ultimately sell under the Offering Agreement, if it chooses to do so, will fluctuate based on a number of factors, including the market price of its common stock during the sales period, the limits it may set in any instruction to sell Shares, and the demand for its common stock during an applicable sales period. Attached hereto as Exhibit 5.1 to this Current Report is the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., relating to the legality of the issuance and sale of the Shares.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 5.1 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 23.1 Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Intensity Therapeutics, Inc. Date: December 4, 2025 By: /s/ Lewis H. Bender Lewis H. Bender Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR